Radar Sleep Monitoring in Type 1 Narcolepsy: Feasibility
Feasibility Study of a Millimeter-Wave Radar Sleep Monitoring System in Patients With Type 1 Narcolepsy
1 other identifier
observational
1
1 country
1
Brief Summary
This study aims to evaluate the clinical feasibility of a millimeter-wave radar sleep monitoring system in the diagnosis of Narcolepsy Type 1 (NT1). Narcolepsy is a chronic central nervous system sleep disorder characterized by excessive daytime sleepiness as its core symptom. NT1 is defined by the presence of cataplexy or reduced cerebrospinal fluid hypocretin-1 (Hcrt-1) levels. The current diagnostic gold standard relies on overnight polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT); however, conventional methods are limited by complex operation, time-consuming procedures, high patient compliance demands, and poor scalability in primary care settings. This prospective, single-center, concurrent validation study plans to enroll 40 clinically diagnosed NT1 patients. Participants will undergo simultaneous PSG/MSLT and millimeter-wave radar sleep monitoring. Using PSG/MSLT as the gold standard, we will assess the consistency and accuracy of the radar system in identifying core parameters, including mean sleep latency (MSL), sleep-onset rapid eye movement period (SOREMP) count, and sleep architecture, while also evaluating data integrity and patient compliance. Key collected indicators include: demographic characteristics, clinical symptoms, Hcrt-1 levels, HLA genotyping, PSG parameters (total sleep time \[TST\], sleep efficiency \[SE\], sleep latency \[SL\], REM latency, SOREMP, sleep stage proportions, apnea-hypopnea index \[AHI\], periodic limb movement index \[PLMI\]), MSLT parameters (MSL, SOREMP count), and radar system parameters (TST, SL, SE, arousal frequency, etc.). Statistical analysis will be performed using SPSS 23.0. Normally distributed continuous variables will be analyzed using independent samples t-tests, non-normally distributed data using Mann-Whitney U tests, and categorical variables using chi-square tests. The study duration is 7 months (May to December 2026). This research may provide a non-contact, convenient, and cost-effective alternative or supplementary monitoring approach for narcolepsy, promoting the application of outpatient and home-based sleep monitoring.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 7, 2026
CompletedFirst Submitted
Initial submission to the registry
June 12, 2026
CompletedFirst Posted
Study publicly available on registry
June 17, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
June 17, 2026
June 1, 2026
8 months
June 12, 2026
June 12, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Whether type 1 narcolepsy is present
The entire process, from enrollment to completion of assessments, takes one day.
Study Arms (1)
narcolepsy group and control group
Eligibility Criteria
Patients with sleep disorders
You may qualify if:
- (1) Patients clinically diagnosed with type 1 narcolepsy; (2) Agree to undergo overnight polysomnography (PSG) and the subsequent daytime multiple sleep latency test (MSLT), with monitoring duration meeting the PSG/MSLT scoring requirements (PSG recording duration ≥ 7 hours, total MSLT procedure duration ≥ 10 hours); (3) Simultaneous data collection using a millimeter-wave radar sleep monitoring system during the monitoring period, with complete and uninterrupted signal acquisition; (4) Complete clinical data available; (5) Willing to participate in this study and sign the informed consent form (if the participant is under 18 years of age, both the participant's assent and the written informed consent of the legal guardian are required).
You may not qualify if:
- (1) Refusal to sign the informed consent form; (2) Inability to complete the full protocol of overnight PSG and the subsequent daytime MSLT due to irregular sleep-wake schedules (e.g., shift work, travel across time zones) or poor compliance; (3) Loss of raw data or poor signal quality during millimeter-wave radar signal acquisition caused by substantial body movements, getting out of bed, environmental interference, or other factors, making effective analysis impossible.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Xijing Hospitallead
Study Sites (1)
First Affiliated Hospital of PLA Air Force Medical University
Xi'an, Shaanxi, China
Related Publications (2)
Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep. 1986 Dec;9(4):519-24. doi: 10.1093/sleep/9.4.519. No abstract available.
PMID: 3809866RESULT[1] American Academy of Sleep Medicine. International classification of sleep disorders-third edition (ICSD-3)[M]. Darien IL: American Academy of Sleep Medicine, 2014
RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 12, 2026
First Posted
June 17, 2026
Study Start
May 7, 2026
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
December 31, 2027
Last Updated
June 17, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share
Involves participant privacy and personally sensitive information, and is subject to data protection regulations.